A randomized phase III trial of sacituzumab–tirumotecan (an antibody-drug conjugated anti-TROP2 pay-linked with a topoisomerase inhibitor) compared to CT (docetaxel or pemetrexed) in 556 patients with NSCLC harboring EGFR mutation or other molecular drivers (including RET alterations) after progressing on first-line TKI (NCT06074588) is ongoing. Here, RET is linked to non-small cell lung carcinoma.